Infant Formula Choline Composition for Myelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Infant formula does not induce identical effects on the body as mother's milk, particularly in terms of brain structure and cognitive functioning, leading to differences in de novo myelination and cognitive potential in formula-fed infants compared to breastfed infants.
Innovation Solution
A synthetic nutritional composition comprising choline, which promotes, supports, or optimizes de novo myelination, brain structure, brain connectivity, intellectual potential, cognitive potential, learning potential, and cognitive functioning in formula-fed subjects, bringing these parameters closer to those observed in breastfed subjects by including additional ingredients like phospholipids, vitamins, minerals, and fatty acid derivatives.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If infant formula is used as an alternative to mother's milk, then feeding options are expanded for infants whose mothers cannot breastfeed, but the brain structure and cognitive functioning outcomes differ from breastfed infants due to insufficient de novo myelination promotion
Solution Approach 1:
The patent modifies the nutritional composition parameters of infant formula by adding specific compounds (choline, phospholipids, sphingomyelin, fatty acids) to change the biochemical environment in the infant brain, thereby promoting de novo myelination and improving brain structure development outcomes to match or approach those of breastfed infants
Solution Approach 2:
The patent creates a composite nutritional formulation combining multiple bioactive compounds (choline as a precursor, phospholipids as structural components, sphingomyelin for membrane integrity, and specific fatty acids for myelin synthesis) that work synergistically to promote myelination, rather than relying on a single substance
2Ease of manufacture
If standard infant formula composition is used, then manufacturing and distribution are simplified, but cognitive potential and learning potential are compromised due to lack of specific myelination-promoting nutrients
Solution Approach 1:
The patent specifies precise concentration ranges for each added compound (e.g., choline at 1-100 mg/L, phospholipids at 0.1-5 g/L, sphingomyelin at 0.1-5 g/L, specific fatty acids at defined concentrations) to optimize myelination promotion while maintaining manufacturing feasibility and cost-effectiveness
Data Source
AI summary
A synthetic nutritional composition comprising choline for use to promote, support or optimise de novo myelination, in particular the de novo myelination trajectory, and/or brain structure, and/or brain connectivity, and/or intellectual potential and/or cognitive potential and/or learning potential and/or cognitive functioning in a subject, in particular a formula fed subject.